VYNE Therapeutics (VYNE) Net Income Growth (3y) (2020 - 2025)
VYNE Therapeutics (VYNE) Net Income Growth (3y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 9.16% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 79.26% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 67.86% |
| Mar 31, 2025 | -26.00% |
| Dec 31, 2024 | 86.43% |
| Jun 30, 2024 | 89.40% |
| Mar 31, 2024 | 90.61% |
| Dec 31, 2023 | 88.42% |
| Sep 30, 2023 | 72.52% |
| Jun 30, 2023 | 95.08% |
| Mar 31, 2023 | 93.71% |
| Dec 31, 2022 | 61.35% |
| Sep 30, 2022 | 79.35% |
| Jun 30, 2022 | 76.68% |
| Mar 31, 2022 | 42.26% |
| Dec 31, 2021 | 57.38% |
| Sep 30, 2021 | 37.37% |
| Jun 30, 2021 | 21.72% |
| Mar 31, 2021 | 53.88% |
| Dec 31, 2020 | 11.59% |
| Sep 30, 2020 | -43.55% |
| Jun 30, 2020 | -199.75% |